Zogenix, Mallinckrodt To End Co-Promotion For SUMAVEL DosePro Effective Jan. 31

(RTTNews) - Zogenix Inc. (ZGNX) and Mallinckrodt (MNK) announced that the co-promotion of SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System will end on January 31, 2014.

SUMAVEL DosePro is Zogenix's first commercial product and was launched in January 2010 for the acute treatment of migraine and cluster headache.

Beginning February 1, 2014, Zogenix will assume full responsibility for the continued commercialization of the brand, with a focus on headache specialists, pain specialists and neurologists who treat a significant number of migraine patients. The early termination of the co-promotion by five months, originally scheduled to end on June 30, 2014, is timed to precede the previously disclosed expansion of the Zogenix sales force planned in February 2014.

The companies have agreed to a detailed customer transition plan with a goal of uninterrupted access and service to prescribers of SUMAVEL DosePro.

Under the amended co-promotion agreement, neither company will incur any penalty payments related to the early termination of the agreement which was originally slated to expire June 30, 2014. Mallinckrodt will continue to earn a service fee based on product sales to its physician segment through January 31, 2014. Zogenix will no longer pay service fees to Mallinckrodt for sales of SUMAVEL DosePro beginning February 1, 2014.

Mallinckrodt and Zogenix entered into the co-promotion agreement June 7, 2012.